定坤丹治疗多囊卵巢综合征的代谢组学与网络药理学机制研究
该研究采用脱氢表雄酮诱导的PCOS大鼠模型,整合代谢组学与网络药理学探讨定坤丹的治疗机制。结果显示定坤丹可改善动情周期紊乱、降低睾酮及LH/FSH比值、抑制异常卵泡形成,其机制与调控CYP17A1等雄激素合成相关靶点有关。
要点
- 定坤丹可改善PCOS大鼠动情周期紊乱并降低睾酮水平。
- 定坤丹抑制卵巢雄激素合成可能与调控CYP17A1等靶点相关。
- 藁本内酯和藏红花苦素是定坤丹抑制睾酮合成的活性成分。
核心结论
- 定坤丹可有效改善脱氢表雄酮诱导的PCOS大鼠症状,其机制与雄激素合成所需的CYP17A1酶相关。
研究设计与样本
- 采用脱氢表雄酮建立PCOS大鼠模型,整合代谢组学与网络药理学策略,并用卵泡膜细胞评估定坤丹及其成分对睾酮合成的影响。
主要发现
- 定坤丹可逆转PCOS大鼠紊乱的动情周期,降低睾酮水平及LH/FSH比值,抑制异常卵泡形成。
- 代谢组学分析初步鉴定出164种血清和172种尿液内源性差异代谢物,类固醇激素生物合成与卵巢类固醇生成是受影响最显著的途径。
- 网络药理学与代谢组学构建了定坤丹治疗PCOS的成分-靶点-通路网络,10个关键靶点中CYP17A1、CYP19A1、STS、AR、ESR1和MYC与卵巢雄激素合成密切相关。
- 在卵泡膜细胞睾酮合成实验中,定坤丹及其两种活性化合物藁本内酯和藏红花苦素显示抑制作用。
关键数值与推荐
- 定坤丹降低PCOS大鼠睾酮水平及LH/FSH比值。
- 代谢组学初步鉴定出164种血清和172种尿液内源性差异代谢物。
- 网络药理学识别出10个关键靶点,其中CYP17A1等6个与卵巢雄激素合成相关。
临床怎么用
- 定坤丹可能通过调控CYP17A1等雄激素合成靶点改善PCOS相关内分泌紊乱,但当前证据限于动物实验,临床应用于PCOS需进一步验证。
局限性
- 研究仅基于脱氢表雄酮诱导的PCOS大鼠模型,尚无临床人体试验数据。
- 代谢组学差异代谢物仅为初步鉴定,其确证需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Dingkun Pill (DKP), a traditional Chinese medicine prescription, was modified from Bujing decoction and Xusijiangsheng pill by the imperial physician in the Qing dynasty (1700' s). It was believed to treat various gynecological diseases by nourishing qi and blood. Accumulating evidence indicates that it is effective in treating polycystic ovary syndrome (PCOS). However, the therapeutic efficacy and mechanism of action DKP against PCOS need to be further elucidated. AIM OF THE STUDY: To investigate the therapeutic effect and action mechanism of DKP against PCOS using an integrated approach of metabolomics and network pharmacology. MATERIALS AND METHODS: The rat model of PCOS was established by dehydroepiandrosterone. An integrated metabolomics and network pharmacology strategy was applied to systemically clarify the mechanism of DKP against PCOS. Theca cells were prepared to evaluate the effect of DKP and its ingredients on testosterone synthesis in vitro. RESULTS: The pharmacological experiments demonstrated that DKP could effectively convert the disordered estrous cyclicity, decrease the level of testosterone and the luteinizing hormone/follicle stimulating hormone ratio, and inhibit abnormal follicle formation in PCOS rats. By metabolomics analysis, 164 serum endogenous differential metabolites and 172 urine endogenous differential metabolites were tentatively identified. Steroid hormone biosynthesis and ovarian steroidogenesis were the most significantly impacted pathways. Based on network pharmacology and metabolomics studies, the ingredient-target-pathway network of DKP in the treatment of PCOS was constructed. Among the 10 key targets, CYP17A1, CYP19A1, STS, AR, ESR1, and MYC were closely involved in ovarian androgen synthesis. In theca cell-based assay of testosterone synthesis, DKP and its two active compounds (ligustilide and picrocrocin) showed inhibitory effects. CONCLUSION: DKP effectively improved symptoms in rats with dehydroepiandrosterone-induced PCOS. The mechanism of DKP in the treatment of PCOS is related to the CYP17A1 enzyme required for androgen synthesis.
引用
- Cai YL, Zhang F, Dou XX, et al. Integrated metabolomics and network pharmacology to reveal the therapeutic mechanism of Dingkun Pill on polycystic ovary syndrome. J Ethnopharmacol. 2022. PMID: 35688255. doi:10.1016/j.jep.2022.115442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。